Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,280Revenue (TTM) $M9,224Net Margin (%)-12.2Altman Z-Score0.2
Enterprise Value $M33,092EPS (TTM) $-3.3Operating Margin %-3.4Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-24.0Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %23.8Quick Ratio1.1Cash flow > EarningsY
Price/Sales0.45-y EBITDA Growth Rate %36.3Current Ratio1.3Lower Leverage y-yN
Price/Free Cash Flow2.1y-y EBITDA Growth Rate %-33.9ROA % (ttm)-2.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-27.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M349ROIC % (ttm)-3.0Gross Margin Increase y-yN

Gurus Latest Trades with VRX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

VRX is held by these investors:



VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
DE SCHUTTER RICHARD UDirector 2017-08-21Buy10,000$14.33-15.35view
DE SCHUTTER RICHARD UDirector 2017-05-11Buy20,000$13.9-12.73view
DE SCHUTTER RICHARD UDirector 2017-03-15Buy10,000$10.812.31view
ValueAct Capital Master Fund, 2017-03-14Buy3,000,000$10.8212.11view
Herendeen PaulEVP and CFO 2017-03-14Buy24,000$10.7213.15view
Pershing Square Capital ManageDirector 2017-03-13Sell18,114,432$1110.27view
Ross Thomas W. Sr.Director 2016-12-14Buy5,000$14.73-17.65view
Pershing Square Capital ManageDirector 2016-12-12Sell3,476,690$14.85-18.32view
KARABELAS ARGERIS NDirector 2016-08-11Buy4,000$24.65-50.79view
Ross Thomas W. Sr.Director 2016-06-13Buy4,000$24.4-50.29view

Press Releases about VRX :

Quarterly/Annual Reports about VRX:

News about VRX:

Articles On GuruFocus.com
Thinking about buying stock in Delta Airlines, The Goldman Sachs Group, MOMO Inc., Micron or Valeant Oct 17 2017 
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Oct 16 2017 
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ (brodalumab) Oct 12 2017 
VRX Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of Valeant Pharmaceuticals Int Oct 05 2017 
Solta Medical Receives FDA 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin Smoot Oct 04 2017 
Solta Medical Receives FDA 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin Smoot Oct 04 2017 
Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe Oct 03 2017 
Valeant Will Release Third-Quarter 2017 Financial Results On November 7 Oct 03 2017 
Valeant Announces Pricing Of Private Offering Of Senior Secured Notes Oct 02 2017 
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Oct 02 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK